Axelar Initiates Phase I/II Clinical Trial on Cancer Patients With the New Anti-Cancer Drug AXL1717

Tue, Jun 17, 2008 08:00 CET

Stockholm, Sweden 2008-06-17

Axelar AB today announced that the company recently has initiated a phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor. The phase I/II clinical trial is primarily.

Axelar Initiates Phase I/II Clinical Trial on Cancer Patients With the New Anti-Cancer Drug AXL1717

Documents & Links